STE Stock Recent News

STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.

Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments.

Steris (STE) reported earnings 30 days ago. What's next for the stock?

Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

STERIS plc (NYSE:STE ) Q3 2025 Earnings Conference Call February 6, 2025 9:00 AM ET Company Participants Julie Winter – Investor Relations Mike Tokich – Senior Vice President and Chief Financial Officer Dan Carestio – President and Chief Executive Officer Conference Call Participants Jacob Johnson – Stephens Brett Fishbin – KeyBanc Michael Polark – Wolfe Research Jason Bednar – Piper Sandler Patrick Wood – Morgan Stanley Mike Matson – Needham & Company Dave Turkaly – Citizens Operator Good day, and welcome to the STERIS plc Third Quarter 2025 Conference Call. All participants will be in a listen-only mode.

STERIS' third-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues. The lowered revenue guidance for fiscal 2025 is concerning.

Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Steris (STE) came out with quarterly earnings of $2.32 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $2.22 per share a year ago.

Medical equipment maker Steris lowered its annual profit forecast on Wednesday, citing the impact of a stronger dollar.

DUBLIN, IRELAND, Feb. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2025 third quarter ended December 31, 2024. Total revenue from continuing operations for the third quarter of fiscal 2025 increased 6% to $1.4 billion compared with $1.3 billion in the third quarter of fiscal 2024. Constant currency organic revenue from continuing operations for the third quarter also increased 6%.